Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in Therapy
Journal Title: Journal of Clinical and Diagnostic Research - Year 2017, Vol 11, Issue 1
Abstract
ABSTRACT Diabetes is a global health emergency of this century. Diabetic nephropathy is the most common microvascular complication associated with Type 2 Diabetes Mellitus (T2DM). T2DM has been reported as a major etiological factor in almost 45% of patients undergoing dialysis due to kidney failure. Lifestyle modifications; cessation of smoking, optimum control of blood glucose, blood pressure and lipids are required to reduce the progression of Diabetic Kidney Disease (DKD). Presently, Dipeptidyl peptidase-4 (DPP-4) inhibitors are preferred in the management of T2DM due to their established efficacy; favorable tolerability including, low risk of hypoglycaemia; weight neutrality and convenient once-a-day dosage. Present evidence suggests that linagliptin and teneligliptin can be used safely without dose adjustments in patients with T2DM with renal impairment, including End Stage Renal Disease (ESRD). There is a limited data about teneligliptin particularly in T2DM patients with renal impairment. The objective of this review is to evaluate efficacy and safety of teneligliptin in T2DM patients with renal impairment, in order to assess the current place in therapy and future prospects of teneligliptin. Reported evidence suggests that teneligliptin has consistent pharmacokinetic in mild, moderate, severe or ESRD, without any need for dose adjustments. Limited data from small sample studies of teneligliptin in DKD patients reported significant improvements in glycaemic parameters. Additionally, there is an improvement in kidney parameters like glycated albumin, urinary albumin and eGFR. There is an evidence of reduction in biomarkers of kidney impairment like P-selectin (sP-selectin), Platelet-Derived Microparticles (PDMPs) and Plasminogen Activator Inhibitor 1 (PAI-1). Clinical significance of these will be known in near future. Thus, teneligliptin has an important place of therapy in the management of T2DM with renal impairment.
Authors and Affiliations
Mohammed Abubaker, Preetesh Mishra, ONKAR C. SWAMI
Keywords
Related Articles
- EP ID EP328376
- DOI 10.7860/JCDR/2017/25060.9228
- Views 169
- Downloads 0
Baseline NT-ProBNP Level as a Risk Predictor of Contrast Induced-Acute Kidney Injury in Acute Coronary Syndrome Patients Undergoing Primary Angioplasty
ABSTRACT Introduction: Contrast Induced Acute Kidney Injury (CI-AKI) is a common complication of invasive cardiovascular procedures. A three-fold higher risk of developing CI-AKI has been observed in patients with Acute...
Method Comparison (Agreement) Studies: Myths and Rationale
Unprecedented technological growth in the last quarter of twentieth century has resulted in improved health care and opened new domains of health care research. This technological leap also facilitated the paradigm shift...
Treatment of Skeletal Class III Malocclusion by Surgery First Orthodontic Approach
Images in Medicine
A Comparative Study of Supraclavicular Brachial Plexus Block with Clonidine as Adjuvant in Two Different Doses in Upper Limb Surgery
ABSTRACT Introduction: Supraclavicular route of brachial plexus block is considered as ‘The Spinal of Arm’, in which local anaesthetic agent is delivered at a point where the three trunks are compactly arranged and carry...
Catalysing Public Healthcare Efficacy: Striking the Right Cords of Leadership
Abstract Introduction: Leaders’ behaviour significantly influences the job satisfaction of the employees. Hospital experience and patient outcomes relate to job satisfaction of employee’s working therein. Aim: Current...